Breast Cancer

From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.

Asking physicians how they perform less-invasive surgeries for breast cancer can help reassure patients that their lymphedema risk is kept in mind.

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

When I underwent surgery for breast cancer, reconstruction was highly recommended, but I decided to remain flat — a decision I think about sometimes.

For some patients with breast cancer, ctDNA may have the potential to predict disease relapse after they have undergone surgery and chemotherapy.

When natural disasters come, they affect everybody, including people dealing with cancer. I hope for speedy recoveries to patients affected by Hurricane Helene.

From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab deruxtecan improved progression-free survival.

Martha Carlson shares her experience of overcoming her fears and embarking on a whitewater rafting adventure despite her stage 4 cancer diagnosis.

A study found that nearly all older patients with ER-positive DCIS could have avoided lymph node removal, researchers have stated.

Just like how Christmas decorations creep into November before Thanksgiving, I hope Pinktober does not creep into September.

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic HER2-low or -ultralow breast cancer.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

As a breast cancer survivor, I’ve learned to navigate the annual sea of pink, but I don’t like it.

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

As a caregiver to my daughter who had breast cancer, pink takes on a new meaning for us — one I’m not quite a fan of.

When given commonly asked questions regarding breast cancer, ChatGPT’s answers were incorrect a quarter of the time and often provided fake references.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to speak out about.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.

I am still struggling to navigate the intrusive questions of well-meaning strangers 17 years after surviving inflammatory breast cancer.

In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda.

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.